Stock comparison
PTC Therapeutics
Summit Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
PTCT
PTC Therapeutics
Market cap
$5.93B
Sector
Healthcare
SMMT
Summit Therapeutics
Market cap
$13.08B
Sector
Healthcare
Overall winner
PTC Therapeutics PTCT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | PTCT | SMMT | Winner |
|---|---|---|---|
| Warren Buffett | 50C | 12F | PTCT |
| Benjamin Graham | 12F | 40D | SMMT |
| Philip Fisher | 54C | 38D | PTCT |
| Peter Lynch | 43D | 64C | SMMT |
| Joel Greenblatt | 2F | 0F | PTCT |
| Charlie Munger | 42D | 15F | PTCT |
| Terry Smith | 50C | 15F | PTCT |
Side-by-side metrics
| Metric | PTCT | SMMT |
|---|---|---|
| Market cap | $5.93B | $13.08B |
| P/E (TTM) | - | - |
| EV/EBIT | 6.4x | - |
| ROIC (TTM) | -2.38% | -2.48% |
| Gross margin | 77.84% | 0.0% |
| Net margin | -22.58% | 0.0% |
| Revenue CAGR 5y | 33.89% | - |
| EPS CAGR 5y | - | 39.68% |
| Debt / Equity | - | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PTCT leads on
- Debt / Equity-vs 0.0x+102%
- Gross margin77.84%vs 0.0%+100%
- ROIC (TTM)-2.38%vs -2.48%+99%
- P/E (TTM)-vs -+61%
SMMT leads on
- EV/EBIT-vs 6.4x+154%
- Net margin0.0%vs -22.58%+100%
- Market cap$13.08Bvs $5.93B+55%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.